Company: HROW
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021562
Chunk: 54

Company: HARROW, INC.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 54
---
 comprised more than 10% of the Company’s Branded revenues for the three and nine months ended September
30, 2025 and one customer who comprised more than 10% of the Company’s Branded revenues for the three and nine months ended September
30, 2024. There were no customers who comprised more than 10% of ImprimisRx revenues for the three and nine months ended September 30,
2025 and 2024. As of September 30, 2025 and December 31, 2024, accounts receivable from two customers accounted for 82% and 94%, respectively,
of total consolidated accounts receivable.

The
Company received its active pharmaceutical ingredients from three main suppliers during the three and nine months ended September 30,
2025 and 2024. These suppliers collectively accounted for 38% and 68% of active pharmaceutical ingredient purchases during the three
and nine months ended September 30, 2025, respectively, and 50% and 51% during the same periods in 2024, respectively.

NOTE
15. SUBSEQUENT EVENTS

The
Company has performed an evaluation of events occurring subsequent to September 30, 2025 through the filing date of this Quarterly Report
on Form 10-Q. Based on its evaluation, no events other than those described below need to be disclosed.

In October
2025, the Company issued 1,658 shares of common stock and received proceeds of $20,000 upon the exercise of options to purchase 1,658
shares of common stock with exercise prices between $7.60 and $21.12 per share.

In
October 2025, the Company issued 1,546 shares of its common stock underlying RSUs held by employees of the Company, net of an aggregate
of 704 shares of the Company’s
common stock were withheld from issuance by the Company for payroll tax obligations totaling $28,000.

30

Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited
condensed consolidated financial statements and the related notes thereto contained in Part I, Item 1 of this Quarterly Report on Form
10-Q (this “Quarterly Report”). Our condensed consolidated financial statements have been prepared and, unless otherwise
stated, the information derived therefrom as presented in this discussion and analysis is presented, in accordance with